Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (RXRX) is a clinical-stage biotechnology pioneer using machine learning and automated experiments to transform drug discovery. This page serves as the definitive source for all official company announcements and verified news coverage.
Investors and industry professionals will find timely updates including clinical trial developments, strategic partnerships, and financial results. Our curated collection features press releases on therapeutic advancements, regulatory milestones, and technology innovations from Recursion's proprietary platform.
Key content categories include quarterly earnings reports, research collaborations, pipeline updates, and executive leadership announcements. All materials are sourced directly from company filings and reputable financial news outlets to ensure accuracy.
Bookmark this page for streamlined access to RXRX's latest progress in decoding complex diseases through computational biology. Check regularly for real-time updates on one of biotech's most technologically advanced drug discovery efforts.
Recursion (NASDAQ: RXRX), a clinical stage TechBio company, has announced its upcoming participation in two major investor conferences in May 2025. The company will be presenting at the Bank of America 2025 Health Care Conference on Tuesday, May 13, and the JP Morgan Global Technology, Media and Communications Conference on Thursday, May 15. Interested parties can access the webcasts through Recursion's Investor Relations website at ir.recursion.com.
Recursion (RXRX), a clinical stage TechBio company, has scheduled the release of its first quarter 2025 financial results on Monday, May 5, 2025, before market open. The company will host a live (L)earnings call at 8:00 am ET / 6:00 am MT / 1:00 pm GMT on the same day.
The earnings call will be broadcast live across multiple social media platforms, including X (formerly Twitter), LinkedIn, and YouTube. Stakeholders, including investors and analysts, can submit their questions through a dedicated online form.
Recursion (NASDAQ: RXRX) will present preliminary clinical data from its Phase 1b/2 TUPELO trial of REC-4881 for familial adenomatous polyposis (FAP) at Digestive Disease Week 2025. The presentation will take place on May 4, 2025, in San Diego.
Key preliminary findings as of February 7, 2025, show:
- 13 patients received 4 mg of REC-4881 daily
- 84.6% experienced at least one treatment-related adverse event
- Most common side effect was rash/dermatitis acneiform (Grade 1 or 2)
- 5 efficacy-evaluable patients showed >30% median reduction in total polyp burden after 12 weeks
REC-4881, identified through Recursion's AI-powered platform, has received Fast Track and Orphan Drug designations from the FDA and European Commission. FAP affects approximately 50,000 people across the US and major European countries, with no current FDA-approved therapies available.
Recursion (NASDAQ: RXRX) has partnered with HealthVerity to enhance its clinical trial capabilities through real-world data integration. The collaboration will give Recursion access to de-identified data covering over 340M lives in the US, which will be integrated into their Recursion OS platform.
This strategic partnership aims to improve clinical trial design, patient population insights, and trial feasibility assessments. Recursion will leverage HealthVerity's comprehensive healthcare data ecosystem to enhance their AI-driven approach, predict patient responses, and optimize study designs while ensuring regulatory compliance.
The integration of HealthVerity's real-world data into Recursion's platforms is expected to streamline clinical development, reduce costs, and accelerate the development of novel therapeutics while maintaining HIPAA compliance and patient privacy standards.
Recursion (NASDAQ: RXRX) and Enamine have announced a collaboration to create AI-enabled targeted compound libraries for drug discovery. The partnership combines Recursion's AI/ML platform (Recursion OS) with Enamine's REAL Space, the world's largest make-on-demand small molecule collection.
The collaboration has resulted in 10 enriched screening libraries comprising over 15,000 newly synthesized compounds, designed to accelerate drug discovery against 100 key clinical targets in challenging biological areas. By leveraging Recursion's AI technology to predict small molecule compatibility with protein targets, the partnership enables the creation of focused libraries that outperform traditional high-throughput screening collections.
As part of the research collaboration, Recursion gained access to tens of thousands of compounds for its internal discovery needs, while helping develop libraries of broad commercial interest. The curated libraries are now available through Enamine's website for customer hit-finding campaigns.
Recursion (RXRX) has initiated dosing in the Phase 1 EXCELERIZE clinical study of REC-3565, a selective MALT1 inhibitor designed for treating relapsed or refractory B-cell lymphomas. The compound, developed using Recursion's AI-powered platform, showed promising preclinical results with durable tumor regressions both as monotherapy and combined with BTK inhibitors.
The study consists of two parts: Part A will evaluate monotherapy dosing, while Part B will assess combination regimens. REC-3565's allosteric design aims to enhance potency and selectivity while potentially reducing liver toxicity risks associated with UGT1A1 inhibition, a common side effect in other MALT1 inhibitors.
Notably, the development timeline was accelerated, with the lead candidate delivered in just 15 months using the Recursion OS platform, which combines physics-based modeling with molecular dynamics and hotspot analysis.
FAQ
What is the current stock price of Recursion Pharmaceuticals (RXRX)?
What is the market cap of Recursion Pharmaceuticals (RXRX)?
